Announcements Trials

Browse Landscape

Phase

Phase 2 2 Phase 4 1 Phase 1/2 1

Status

Completed 7 Terminated 4 Active not recruiting 4 Withdrawn 2 Recruiting 2 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

Bevacizumab 14 Injections 13 Drug Therapy 10 Gemcitabine 9 venetoclax 7 toripalimab 7 pembrolizumab 7 Specimen Handling 7 Magnetic Resonance Spectroscopy 7 Cyclophosphamide 7 irinotecan sucrosofate 6 Temozolomide 6 Fluorouracil 6 tislelizumab 5 fludarabine 5 N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 5 HMPL-013 5 Etoposide 5 Dexamethasone 5 Cisplatin 5 Carboplatin 5 Capecitabine 5 Biopsy 5 sintilimab 4 lenvatinib 4 Rituximab 4 Radiotherapy 4 Pemetrexed 4 Paclitaxel 4 Oxaliplatin 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Not yet recruiting × niraparib × Clear all

NCT06258018 2024-08-30

ONC-2022-001

Istituto Clinico Humanitas

Phase 1/2 Not yet recruiting

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡